← Eichor
Study identifier: NCT03596476 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy

Condition: Gastro-esophageal Reflux Disease  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants330
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Gastro-esophageal reflux disease (GERD) is defined as the reflux of gastric content into the esophagus that causes troublesome symptoms or complications. Nine to 30% of the population suffers from GERD-suggestive symptoms (heartburn, regurgitation, chest pain, chronic couch, sore throat). In the absence of warning signs, proton pump inhibitors (PPI) are prescribed as first-line treatment. However, 20 to 60% of patients are unsatisfied because of persistent symptoms when taking PPI. Causes of persistent symptoms are: erroneous diagnosis of GERD (up to 50% of PPI non-responders), rumination syndrome, excessive weakly acid reflux on PPI due to defective esophago-gastric junction or an excessive number of transient lower esophageal sphincter relaxations (main mechanism of GERD), poor acid secretion inhibition on PPI, and non-compliance to therapy. Complementary examinations are indicated to explain persistent GERD symptoms. Upper gastro-intestinal endoscopy is performed first to rule out an esophageal tumor and to identify erosive esophagitis, a specific sign of GERD. However, it is normal in up to 70% of symptomatic GERD patients. Direct detection of reflux episodes is then requested to confirm GERD. The gold standard for reflux detection is the ambulatory measurement of esophageal pH for 24 to 96 hours using a catheter (catheter-based pH-monitoring) or a capsule clipped into the esophagus (wireless pH-monitoring). Reflux episodes are defined as an esophageal pH \< 4. Another me…

This description comes directly from the study's public registry record.

Talk to the study team

Sabine ROMAN, MD  ·  4 72 11 01 36  ·  sabine.roman@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (7)

Service d'Hepato-Gastroenterologie - Hôpital Trousseau - CHU de ToursChambray-lès-Tours, FranceRecruiting
Service d'Hepato-Gastroenterologie - Hôpital Louis Mourier - APHPColombes, FranceRecruiting
Service d'Explorations Fonctionnelles Digestives - Hôpital Edouard Herriot - HCLLyon, FranceRecruiting
Service d'Hepato-Gastroenterologie - Hôtel Dieu - CHU de NantesNantes, FranceRecruiting
Service d'Hepato-Gastroenterologie - Hôpital Haut Lévêque - CHU de BordeauxPessac, FranceRecruiting
Service d'Hepato-Gastroenterologie - Hôpital Pontchaillou- CHU de RennesRennes, FranceRecruiting
Service de Physiologie Digestive, Respiratoire, Urinaire et Sportive - CHU de RouenRouen, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03596476